HUMANIZED COMPLEMENT 5A RECEPTOR 1 ANTIBODIES AND METHODS OF USE THEREOF

The present disclosure provides, among other things, two different formats of humanized antibodies against human complement component 5a receptor 1. The disclosure also provides a method of treating a subject having dysfunctions of C5a/C5aR1 axis pathway, including but not limited to ANCA-associated...

Full description

Saved in:
Bibliographic Details
Main Authors BABCOCK Gregory, RAMAKRISHNAN Boopathy, BOOTH Brian, OLINSKI Lauren, SHRIVER Zachary, VISWANATHAN Karthik, WOLLACOTT Andrew
Format Patent
LanguageEnglish
Spanish
Published 25.09.2023
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The present disclosure provides, among other things, two different formats of humanized antibodies against human complement component 5a receptor 1. The disclosure also provides a method of treating a subject having dysfunctions of C5a/C5aR1 axis pathway, including but not limited to ANCA-associated vasculitis, comprising administering to the subject in need thereof a an effective amount of antibody or a nucleic encoding an antibodies binding to C5aR1 described herein, and wherein administering results in a decrease in symptoms associated with C5a/C5aRl associated dysfunction in the subject. La presente descripción proporciona, entre otras cosas, dos formatos diferentes de anticuerpos humanizados contra el receptor I del componente 5a del complemento humano. La descripción también proporciona un método para tratar a un sujeto que tiene disfunciones de la vía del eje C5a/C5aR1, que incluyen, pero sin limitarse a, vasculitis asociada a ANCA, que comprende administrar al sujeto que lo necesita una cantidad efectiva de anticuerpo o un nucleico que codifica unos anticuerpos que se unen a C5aR1 descritos en la presente descripción, y en donde la administración da como resultado una disminución de los síntomas asociados con la disfunción asociada a C5a/C5aR1 en el sujeto.
Bibliography:Application Number: MX20230008302